Department of Biochemistry and Molecular Biology, The University of Texas Medical Branch , Galveston, Texas 77555, United States.
J Proteome Res. 2012 Mar 2;11(3):1512-20. doi: 10.1021/pr2003165. Epub 2012 Feb 15.
A multiplexed peptide quantification strategy using the iTRAQ reagent has been described for relative measurements of peptides in digested protein mixtures. To validate the chemical specificity of the iTRAQ reaction, we have performed a detailed study of iTRAQ reactivity with two sets of synthetic peptides. The first set of peptides had sequences of Tyr-Xaa-Ser-Glu-Gly-Leu-Ser-Lys and Tyr-Xaa-Ser-Glu-Tyr-Leu-Ser-Lys where Xaa = Ala, Pro, Trp, Tyr, or Glu and was designed to study the extent of O-acylation by iTRAQ, especially hydroxyl-containing residues in different positions. The second set of peptides included Ala-Ser-Glu-His-Ala-Xaa-Tyr-Gly where Xaa = Ser, Thr, or Tyr and was selected to investigate the effect of histidyl residues separated by one amino acid residue from seryl, tyrosyl, or threonyl residues. Our findings indicated that, in addition to variable levels of O-acylation of nonsequence-specific hydroxyl-containing residues, significant sequence-specific O-acylation of seryl, threonyl, and tyrosyl hydroxyls occurred when separated one residue removed from a histidyl residue, that is, (Tyr/Ser)-Xaa-His or His-Xaa-(Tyr/Ser/Thr). This behavior was verified by a separate spiking experiment of one of the first set of peptides into Escherichia coli protein extracts, followed by retention time targeted LC-MS/MS to demonstrate the occurrence of modifications in a complex mixture. These sequence-dependent O-acylation modifications can be confounding factors to accurate MS quantification. Reversal of peptide O-acylation by the iTRAQ reagent can be accomplished by reaction with hydroxylamine with virtually no cleavage of N-acylation and is a recommended modification of the iTRAQ protocol for many applications.
一种使用 iTRAQ 试剂的多重肽定量策略已被描述用于在消化的蛋白质混合物中相对测量肽。为了验证 iTRAQ 反应的化学特异性,我们对两种合成肽进行了详细研究。第一组肽具有 Tyr-Xaa-Ser-Glu-Gly-Leu-Ser-Lys 和 Tyr-Xaa-Ser-Glu-Tyr-Leu-Ser-Lys 的序列,其中 Xaa = Ala、Pro、Trp、Tyr 或 Glu,旨在研究 iTRAQ 的 O-酰化程度,特别是不同位置的羟基含有的残基。第二组肽包括 Ala-Ser-Glu-His-Ala-Xaa-Tyr-Gly,其中 Xaa = Ser、Thr 或 Tyr,被选择用于研究与丝氨酸、苏氨酸或苏氨酸残基相隔一个氨基酸残基的组氨酸残基的影响。我们的研究结果表明,除了非序列特异性羟基含有的残基的可变水平 O-酰化外,当与组氨酸残基相隔一个残基时,丝氨酸、苏氨酸和酪氨酸的羟基会发生显著的序列特异性 O-酰化,即(Tyr/Ser)-Xaa-His 或 His-Xaa-(Tyr/Ser/Thr)。这一行为通过将第一组肽之一的单独加标实验到大肠杆菌蛋白质提取物中,然后进行保留时间靶向 LC-MS/MS 来证明在复杂混合物中发生修饰来验证。这些依赖于序列的 O-酰化修饰可能是准确 MS 定量的混杂因素。iTRAQ 试剂通过与羟胺反应可以逆转肽的 O-酰化,几乎没有 N-酰化的裂解,这是许多应用中推荐的 iTRAQ 方案的修饰。